Last updated: July 31, 2026
Lucentis, or ranibizumab, remains an FDA-approved anti-VEGF treatment for neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, macular edema after retinal vein occlusion, and myopic choroidal neovascularization. Its clinical position is established, but its commercial profile is under sustained pressure from aflibercept, faricimab, biosimilar ranibizumab products and lower-cost off-label bevacizumab.
The principal market transition is from branded Lucentis to ranibizumab biosimilars and alternative anti-VEGF agents. By 2024, FDA-approved biosimilars Byooviz and Cimerli had created a lower-price substitute market in the United States. Lucentis remains clinically relevant, particularly where physicians value its long safety history, but its revenue base is structurally declining.
What is Lucentis and how does ranibizumab work?
Lucentis is a recombinant humanized monoclonal antibody fragment targeting vascular endothelial growth factor A, or VEGF-A. It binds VEGF-A and reduces abnormal vascular permeability and angiogenesis in the retina.
| Attribute |
Lucentis |
| Active ingredient |
Ranibizumab |
| Drug class |
Anti-VEGF monoclonal antibody fragment |
| Original developer |
Genentech |
| U.S. commercial rights |
Genentech/Roche |
| Ex-U.S. commercial rights |
Novartis |
| Primary route |
Intravitreal injection |
| Common vial dose |
0.5 mg or 0.3 mg in 0.05 mL |
| FDA approval |
2006 |
| Main competitors |
Eylea, Eylea HD, Vabysmo, Avastin, Byooviz, Cimerli |
| Delivery-platform successor |
Susvimo, a ranibizumab port-delivery system |
Lucentis was derived from the same antibody lineage as bevacizumab, but it is an antigen-binding fragment designed for ophthalmic use. Bevacizumab is a full-length antibody used off label in ophthalmology, while ranibizumab was developed specifically for intraocular administration.
What FDA-approved indications does Lucentis have?
Lucentis is approved for several retinal vascular disorders:
| Indication |
U.S. approval status |
Commercial relevance |
| Neovascular age-related macular degeneration |
FDA approved |
Original and historically largest indication |
| Macular edema following retinal vein occlusion |
FDA approved |
Includes branch and central RVO |
| Diabetic macular edema |
FDA approved |
Major chronic-use indication |
| Diabetic retinopathy |
FDA approved |
Overlaps with DME treatment population |
| Myopic choroidal neovascularization |
FDA approved |
Smaller specialty indication |
Treatment is administered by intravitreal injection, with dosing based on the indication and clinical response. Monthly loading and maintenance regimens were central to the original pivotal studies. In current practice, clinicians often use treat-and-extend schedules, although dosing intervals may differ from the original trial protocols.
The FDA prescribing information identifies endophthalmitis, retinal detachment, increased intraocular pressure, traumatic cataract, intraocular inflammation and arterial thromboembolic events as important risks. Systemic exposure is lower than with many systemic biologics, but VEGF inhibition creates a class-related cardiovascular and cerebrovascular safety consideration.[1]
What were the pivotal Lucentis clinical trials?
Neovascular age-related macular degeneration
The principal AMD evidence came from the MARINA and ANCHOR studies.
| Trial |
Population |
Design |
Main result |
| MARINA |
Minimally classic or occult choroidal neovascularization |
Randomized, sham-controlled |
Monthly ranibizumab preserved or improved vision compared with sham |
| ANCHOR |
Predominantly classic choroidal neovascularization |
Randomized, active and control arms |
Ranibizumab produced superior visual outcomes to verteporfin therapy |
MARINA established the benefit of monthly ranibizumab in predominantly occult or minimally classic lesions. ANCHOR established ranibizumab as a standard treatment for predominantly classic lesions. Both trials changed the treatment model for wet AMD by showing that an anti-VEGF agent could produce visual improvement rather than only slow deterioration.[2,3]
Diabetic macular edema
The RISE and RIDE trials evaluated ranibizumab in diabetic macular edema.
| Trial |
Population |
Main finding |
| RISE |
Center-involving diabetic macular edema |
Ranibizumab improved the probability of clinically meaningful visual gain |
| RIDE |
Center-involving diabetic macular edema |
Results supported the same efficacy pattern as RISE |
The trials supported approval of Lucentis for DME and demonstrated that repeated anti-VEGF therapy could improve visual acuity in diabetic retinal disease. The treatment burden, injection frequency and need for long-term monitoring remain important commercial and clinical limitations.[4]
Retinal vein occlusion
The BRAVO and CRUISE studies evaluated macular edema associated with branch and central retinal vein occlusion.
| Trial |
Disease |
Result |
| BRAVO |
Branch retinal vein occlusion |
Ranibizumab improved visual acuity and reduced retinal thickness |
| CRUISE |
Central retinal vein occlusion |
Ranibizumab improved visual acuity and reduced edema |
These studies supported the RVO indication and expanded Lucentis beyond AMD. The clinical need remains significant, but the RVO segment is smaller than the AMD market and competes with other anti-VEGF therapies.[5,6]
What is the current Lucentis clinical-trial pipeline?
Lucentis is no longer a major late-stage innovation asset. The principal clinical development activity has shifted from the original Lucentis injection to ranibizumab delivery systems and reformulated anti-VEGF products.
Susvimo and port-delivery development
Susvimo is a surgically implanted reservoir that continuously delivers ranibizumab. It was approved by the FDA in 2021 for neovascular AMD. The ARCHWAY phase 3 study showed that port-delivery ranibizumab could maintain visual acuity with fixed refill intervals compared with monthly intravitreal injections.[7]
The original Susvimo system experienced a voluntary recall and commercial interruption related to implant septum integrity and drug leakage concerns. Roche later reported a U.S. relaunch after manufacturing and design-related remediation. This history is commercially important because it limits the extent to which the port-delivery system can replace conventional Lucentis injections.
Later studies expanded the delivery-platform strategy:
- Pagoda evaluated Susvimo in diabetic macular edema.
- Pavilion evaluated Susvimo in diabetic retinopathy.
- Additional studies examined treatment intervals and disease populations.
These studies concern the ranibizumab delivery platform rather than an expansion of the conventional Lucentis vial franchise. The strategic value lies in reducing injection frequency and creating device-related differentiation after conventional ranibizumab faced biosimilar competition.
Current development direction
The Lucentis franchise has moved from molecule innovation to lifecycle management:
- biosimilar defense and contracting;
- longer-duration delivery;
- port-delivery technology;
- treatment of diabetic retinal disease;
- protection of physician and payer access.
The competitive clinical benchmark has also changed. Faricimab, marketed as Vabysmo, targets both VEGF-A and angiopoietin-2 and has produced longer dosing intervals in AMD and DME studies. Aflibercept, marketed as Eylea, has a large real-world evidence base and an extended-dose formulation, Eylea HD. These products reduce Lucentis's clinical differentiation.
What is the Orange Book status of Lucentis?
Lucentis has historically been protected by composition-of-matter, formulation, manufacturing and method-of-use patents. The core U.S. patent estate has largely expired or moved beyond the period of practical exclusivity for conventional ranibizumab.
| Patent category |
Commercial role |
Status |
| Ranibizumab composition claims |
Protected the original molecule |
Core term expired in the United States |
| Ophthalmic formulation claims |
Addressed injectable formulations and stability |
Certain claims extended protection beyond the base composition term |
| Method-of-use claims |
Covered treatment of retinal disorders |
Remaining claims may be relevant to specific indications and dosing |
| Port-delivery claims |
Protect Susvimo implant, refill and delivery technology |
Separate lifecycle estate with later expirations |
| Manufacturing claims |
Address production and purification |
Potential barrier to biosimilar development and process replication |
The FDA Orange Book should be reviewed for the current listed patent set because listings can change through delisting, expiration, pediatric extensions and product-specific updates. The principal commercial issue is that the conventional Lucentis product no longer has the level of blocking patent protection associated with a newly launched biologic.[8]
When did Lucentis lose core U.S. exclusivity?
Lucentis's principal U.S. biologic and patent protections were concentrated in the late 2021-2022 period. Biosimilar entry began after settlement agreements and regulatory approvals, although commercial launch timing depended on the terms negotiated between Roche/Genentech and biosimilar developers.
Regulatory exclusivity and patent exclusivity are separate:
- FDA biologic reference-product exclusivity protected the reference product for 12 years from first licensure under the Biologics Price Competition and Innovation Act.
- Patent protection depended on individual patent claims and expiration dates.
- Settlement agreements could authorize a biosimilar launch before the latest asserted patent expiry.
The practical loss of exclusivity occurred through staged biosimilar entry rather than a single generic event.
Which companies are challenging Lucentis with biosimilars?
Two ranibizumab biosimilars have been central to U.S. competition.
| Product |
Developer |
FDA designation |
Approval |
Commercial position |
| Byooviz |
Samsung Bioepis and Biogen |
Ranibizumab-nuna |
2021 |
First FDA-approved ranibizumab biosimilar |
| Cimerli |
Coherus BioSciences |
Ranibizumab-eqrn |
2022 |
Interchangeable biosimilar designation; broader labeled indications |
Byooviz was the first FDA-approved biosimilar to Lucentis. Cimerli received an interchangeable designation, giving it a stronger substitution position under applicable state pharmacy laws and payer policies.[9,10]
Biosimilar competition is more complex for ophthalmic injectables than for conventional retail drugs. Physicians, hospitals, specialty pharmacies and payers influence product selection. Buy-and-bill reimbursement, acquisition cost, payer formulary placement and confidence in injection-device handling are important commercial factors.
How strong is the Lucentis patent estate?
The conventional Lucentis patent estate is moderate to weak against approved biosimilar competition. Its strongest remaining barriers relate to specific formulations, manufacturing processes, device integration and delivery schedules rather than the basic ranibizumab molecule.
Patent strength by asset
| Asset |
Patent strength |
Reason |
| Original Lucentis molecule |
Low |
Core exclusivity has ended |
| Standard intravitreal formulation |
Low to moderate |
Biosimilars have entered the market |
| Specific manufacturing processes |
Moderate |
Process claims can complicate development but may be designed around |
| Dosing and method-of-use claims |
Moderate |
Enforcement depends on claim scope and product labeling |
| Susvimo implant |
Moderate to strong |
Device, formulation and combination claims create a separate estate |
| Pediatric or narrow indication claims |
Variable |
Value depends on label and prescriber behavior |
A biosimilar developer can avoid some method-of-use exposure through a skinny label or indication carve-out. This creates a continuing litigation and regulatory distinction between the approved product label and the actual clinical uses of ranibizumab.
What patent litigation and settlement agreements affect Lucentis?
The major U.S. biosimilar entrants negotiated with Genentech and Roche before launch. These agreements addressed patent litigation risk and provided defined launch rights. The commercial result was controlled entry rather than an immediate open-market collapse.
Lucentis-related biosimilar litigation generally involves:
- patent infringement claims under the BPCIA;
- patent dance disclosures;
- formulation and manufacturing patents;
- use patents for retinal indications;
- launch-date agreements;
- settlement terms affecting commercialization.
The settlement structure is commercially important because it can preserve branded revenue through a delayed biosimilar launch while giving the biosimilar developer a legally defined entry date. It also reduces the probability of a full injunction against an FDA-approved biosimilar when the parties have agreed to a launch timetable.
What is the current market position of Lucentis?
Lucentis operates in a mature anti-VEGF market with high clinical demand but falling branded share.
Competitive set
| Drug |
Molecule |
Principal advantage |
| Lucentis |
Ranibizumab |
Long clinical history and established safety record |
| Byooviz |
Ranibizumab biosimilar |
Lower-cost alternative |
| Cimerli |
Ranibizumab biosimilar |
Interchangeability and broad label |
| Eylea |
Aflibercept |
Strong efficacy, extensive use and established payer access |
| Eylea HD |
High-dose aflibercept |
Longer dosing interval potential |
| Vabysmo |
Faricimab |
Dual VEGF-A/Ang-2 mechanism and extended intervals |
| Avastin |
Bevacizumab |
Very low acquisition cost when compounded for ophthalmic use |
Avastin remains a major economic competitor because ophthalmologists can use compounded bevacizumab off label at a fraction of the cost of branded anti-VEGF products. Compounding quality, supply reliability, reimbursement and liability considerations influence adoption.
Vabysmo and Eylea HD have more favorable differentiation in treatment interval than conventional Lucentis. Lucentis therefore competes primarily through brand familiarity, contracting, physician continuity and access programs.
Revenue exposure
Lucentis was once one of the largest ophthalmology products globally. Its revenue declined after:
- the emergence of Eylea;
- increased use of off-label Avastin;
- biosimilar entry;
- payer pressure;
- adoption of longer-acting anti-VEGF products;
- the transition of Roche and Novartis portfolios toward newer assets.
The relevant revenue pool is still substantial because AMD, DME and RVO require chronic or repeated treatment. The share available to branded Lucentis is contracting. Lucentis should be analyzed as a declining mature product rather than a growth asset.
What is the Lucentis market projection for 2024-2030?
The anti-VEGF retinal market is expected to grow in patient volume while conventional Lucentis revenue declines. Aging populations, diabetes prevalence and improved retinal diagnosis support demand. Price erosion and product substitution offset that volume growth for Lucentis.
Base-case projection
| Period |
Lucentis commercial outlook |
Main driver |
| 2024-2025 |
Declining sales and share |
Biosimilar contracting and payer substitution |
| 2026-2027 |
Continued erosion |
Wider Cimerli and Byooviz access, Eylea HD and Vabysmo adoption |
| 2028-2030 |
Mature residual franchise |
Brand-prescription persistence, selected contracts and international markets |
A reasonable base case is a high-single-digit to low-double-digit annual decline in branded Lucentis revenue through 2030. The decline can be faster in price-sensitive U.S. payer channels and slower in markets where biosimilar substitution is limited or reimbursement remains brand favorable.
Scenario analysis
| Scenario |
Assumption |
2030 outcome |
| Downside |
Rapid biosimilar substitution and strong Vabysmo/Eylea HD adoption |
Lucentis becomes a small residual brand |
| Base case |
Gradual biosimilar uptake with continued chronic retinal demand |
Meaningful but declining specialty revenue |
| Upside |
Delayed payer conversion, supply constraints for competitors or stronger delivery-platform adoption |
Slower erosion, but limited growth |
Susvimo could improve the ranibizumab franchise if Roche can maintain implant reliability, expand diabetic retinal indications and demonstrate a meaningful reduction in treatment burden. The device also creates a separate reimbursement and procedure pathway, which may limit rapid adoption.
What generic entry risks exist for Lucentis?
Lucentis faces biosimilar rather than traditional small-molecule generic entry. The main risks are:
- lower reimbursement for the reference product;
- mandatory or incentivized payer substitution;
- physician adoption of interchangeable Cimerli;
- hospital and specialty-pharmacy tendering;
- erosion of contracting leverage;
- increased use of compounded bevacizumab;
- migration to longer-acting Eylea HD or Vabysmo.
The largest risk is cumulative price and volume erosion. A single biosimilar may not cause severe displacement, but multiple products and payer-directed switching can materially reduce branded demand.
How does Lucentis compare with Eylea and Vabysmo?
| Factor |
Lucentis |
Eylea/Eylea HD |
Vabysmo |
| Mechanism |
VEGF-A inhibition |
VEGF-A and placental growth factor inhibition |
VEGF-A and Ang-2 inhibition |
| Delivery |
Intravitreal injection; Susvimo implant option |
Intravitreal injection |
Intravitreal injection |
| Biosimilar pressure |
High |
Increasing |
Limited as of 2024 |
| Dosing differentiation |
Conventional Lucentis burden; Susvimo option |
Stronger with Eylea HD |
Extended intervals in pivotal studies |
| Brand maturity |
Mature and declining |
Large established franchise |
Growth product |
| Cost position |
Pressured by biosimilars |
Premium branded pricing |
Premium branded pricing |
| Clinical familiarity |
Very high |
Very high |
Rapidly increasing |
Lucentis retains strong evidence and physician familiarity. It lacks the commercial growth profile of newer agents. The most defensible part of the franchise is Susvimo, not the conventional vial.
What regulatory milestones matter for Lucentis?
Key FDA milestones include:
| Year |
Milestone |
| 2006 |
Initial FDA approval for neovascular AMD |
| 2010 |
Expansion into macular edema after RVO |
| 2012 |
Approval for diabetic macular edema |
| 2017 |
Approval for myopic choroidal neovascularization |
| 2021 |
FDA approval of Susvimo for neovascular AMD |
| 2021 |
FDA approval of Byooviz |
| 2022 |
FDA approval and interchangeability designation for Cimerli |
| 2023-2024 |
Continued delivery-platform and retinal disease development |
Lucentis's regulatory foundation is strong. The commercial issue is no longer whether the product is clinically validated. It is whether the reference product can maintain share against lower-priced ranibizumab and newer anti-VEGF therapies.
Key Takeaways
- Lucentis is an established ranibizumab anti-VEGF therapy with approvals across AMD, DME, diabetic retinopathy, RVO and myopic CNV.
- MARINA, ANCHOR, RISE, RIDE, BRAVO and CRUISE established its core efficacy profile.
- The conventional Lucentis molecule has lost its principal U.S. exclusivity protections.
- Byooviz and Cimerli are the main U.S. ranibizumab biosimilar competitors.
- Cimerli's interchangeable designation increases substitution risk.
- Eylea HD and Vabysmo are stronger growth competitors because of dosing-interval and mechanism differentiation.
- Susvimo is the principal lifecycle-management asset associated with ranibizumab.
- Lucentis revenue is expected to decline through 2030, with the base case indicating high-single-digit to low-double-digit annual erosion.
- The strongest remaining IP positions concern delivery systems, manufacturing, formulations and narrow method-of-use claims.
- Market demand for retinal anti-VEGF treatment should grow even as branded Lucentis share contracts.
FAQs
Is Lucentis still FDA approved?
Yes. Lucentis remains FDA approved for several retinal diseases, including neovascular AMD, DME, diabetic retinopathy, macular edema after RVO and myopic CNV.
Are Byooviz and Cimerli interchangeable with Lucentis?
Byooviz is an FDA-approved ranibizumab biosimilar. Cimerli received an interchangeable biosimilar designation, subject to applicable substitution laws and payer rules.
Is Lucentis safer than Avastin?
Lucentis has an indication-specific ophthalmic development and regulatory history. Avastin is used off label in ophthalmology and has a different formulation, preparation and administration pathway. Comparative safety depends on product handling, patient characteristics and clinical context.
What is the difference between Lucentis and Susvimo?
Lucentis is generally administered by repeated intravitreal injection. Susvimo is a surgically implanted ranibizumab delivery system designed to reduce injection frequency.
Will Lucentis sales continue after 2030?
Yes, but the product is more likely to retain a residual specialty market than return to historical peak sales. Brand loyalty, contracting, international reimbursement and delivery-platform adoption will determine the remaining revenue base.
References
-
U.S. Food and Drug Administration. (2023). Lucentis prescribing information. Genentech, Inc.
-
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, 355(14), 1419-1431.
-
Brown, D. M., Kaiser, P. K., Michels, M., Souied, E., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine, 355(14), 1432-1444.
-
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., et al. (2012). Ranibizumab for diabetic macular edema: Results from the RISE and RIDE phase III randomized trials. Ophthalmology, 119(4), 789-801.
-
Brown, D. M., Campochiaro, P. A., Singh, R. P., Li, Z., Gray, S., Saroj, N., Rundle, A. C., et al. (2010). Ranibizumab for macular edema following central retinal vein occlusion. Ophthalmology, 117(6), 1124-1133.
-
Campochiaro, P. A., Heier, J. S., Feiner, L., Gray, S., Saroj, N., Rundle, A. C., & Murahashi, W. Y. (2010). Ranibizumab for macular edema following branch retinal vein occlusion. Ophthalmology, 117(6), 1102-1112.
-
Holekamp, N. M., Liu, Y., Yeh, W. S., Yang, S., Mathieson, I., & McCannel, C. A. (2022). Clinical efficacy and safety of the port delivery system with ranibizumab in neovascular age-related macular degeneration. Ophthalmology, 129(3), 295-307.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2021). FDA approves first biosimilar to Lucentis. FDA.
-
U.S. Food and Drug Administration. (2022). FDA approves Cimerli, a biosimilar to Lucentis. FDA.
